| Literature DB >> 24719549 |
Serap Basoglu1, Serdar Ulker2, Sengul Alpay-Karaoglu2, Neslihan Demirbas1.
Abstract
Ethyl 4-amino-2-fluorophenylpiperazin-1-carboxylates containing aEntities:
Keywords: 1,2,4-Triazole; 1,3-Oxa(thia)zole; 5-Oxo-1,3-oxazolidine; 6-Aminopenicillanic acid; 7-Aminocephalosporanic acid; Biological activity; Piperazine
Year: 2013 PMID: 24719549 PMCID: PMC3973943 DOI: 10.1007/s00044-013-0898-4
Source DB: PubMed Journal: Med Chem Res ISSN: 1054-2523 Impact factor: 1.965
Scheme 1i 3,4-Difluoronitrobenzene in ethanol, reflux for 6 h. ii Pd–C, hydrazine hydrate in n-butanol, reflux for 7 h. iii Indole-3-carboxaldehyde in absolute ethanol, irradiation by MW at 150 W, 110 °C for 30 min. iv Benzylisothiocyanate in absolute ethanol, reflux for 10 h. v Ethyl bromoacetate in absolute ethanol, dried sodium acetate, reflux for 13 h. vi 4-Chlorophenacylbromide in absolute ethanol, dried sodium acetate, reflux for 11 h
Scheme 2i Ethyl bromoacetate, Et3N, THF, rt for 14 h. ii Hydrazine hydrate in ethanol, reflux for 14 h. iii 4-Fluorophenylisothiocyanate or phenylisothiocyanate in absolute ethanol, reflux for 10 h. iv H2SO4, rt for 2 h. v NaOH in water, reflux for 3 h. vi 7-Aca, HCHO, Et3N in THF, rt, for 4 h. vii 6-Apa, HCHO, Et3N in THF, rt, for 4 h. vii 4-Chlorophenacylbromide in absolute ethanol, dried sodium acetate, reflux for 12 h
Scheme 3i 3-Hydroxy-4-phenoxybenzaldehyde, pyridine-4-carbaldehyde, 2-hydroxybenzaldehyde in absolute ethanol, irradiation by MW at 200 W, 140 °C for 30 min. ii CS2 and KOH in ethanol, reflux for 13 h. iii 7-Aca, HCHO, Et3N in THF, rt, for 4 h. iv 6-Apa, HCHO, Et3N in THF, rt, for 4 h
Screening for antimicrobial activity of the compounds (50 μL)
| Comp. no | Microorganisms and inhibition zone (mm) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ec | Yp | Pa | Sa | Ef | Bc | Ms | Ca | Sc | |
|
| – | – | – | – | – | 6 | – | – | – |
|
| – | – | – | 11 | – | 6 | – | 15 | 15 |
|
| 8 | 8 | – | – | – | 10 | 8 | 8 | |
|
| – | – | – | – | – | – | – | – | – |
|
| – | – | – | – | – | – | – | 8 | 8 |
|
| 6 | 6 | – | – | – | 8 | 20 | 15 | 15 |
|
| – | – | – | – | – | 20 | 10 | 10 | |
|
| 8 | 8 | 6 | 6 | – | 6 | 25 | 20 | 10 |
|
| – | – | – | – | – | – | – | 6 | 7 |
|
| – | – | – | – | – | – | – | – | – |
|
| – | – | – | – | – | – | – | – | – |
|
| – | – | – | – | – | 6 | – | – | – |
|
| – | – | – | – | – | 6 | – | 7 | – |
|
| – | – | – | – | – | 6 | – | – | – |
|
| – | – | – | 10 | – | 6 | – | – | – |
|
| – | – | – | – | – | – | – | 6 | 6 |
|
| – | – | 6 | – | – | – | – | 8 | 10 |
|
| – | – | – | 6 | 6 | – | – | 8 | – |
|
| – | 6 | 6 | 6 | – | – | – | 10 | – |
|
| 8 | – | – | 6 | 10 | – | – | 6 | 10 |
|
| 9 | 9 | 8 | 13 | – | 16 | 14 | 6 | 12 |
|
| – | – | 6 | 10 | – | 6 | – | 8 | 12 |
|
| – | – | 6 | – | 8 | – | – | 9 | 6 |
|
| – | – | – | – | – | – | – | 8 | – |
|
| – | – | 6 | – | 8 | – | – | 8 | 6 |
|
| – | – | – | 10 | 6 | 6 | 15 | 8 | 12 |
|
| 8 | 8 | – | 6 | 10 | 10 | 20 | 10 | 8 |
|
| 9 | 8 | 15 | 9 | 10 | 18 | 8 | 12 | |
| Amp. | 10 | 18 | 18 | 35 | 10 | 15 | |||
| Strep. | 35 | ||||||||
| Flu. | 25 | >25 | |||||||
(–), no activity
Ec, Escherichia coli ATCC 25922; Yp, Yersinia pseudotuberculosis ATCC 911; Pa, Pseudomonas aeruginosa ATCC 43288; Sa, Staphylococcus aureus ATCC 25923; Ef, Enterococcus faecalis ATCC 29212; Bc, Bacillus cereus 702 Roma; Ms, M. smegmatis ATCC607; Ca, Candida albicans ATCC 60193; Sc, Saccharomyces cerevisiae RSKK 251; Amp., Ampicillin; Strep., Streptomycin; Flu., Fluconazole
Inhibitory activities of the synthesized compounds against Jack Bean urease
| Compound | % Inhibition ± S.D. | IC50 ± S.D. |
|---|---|---|
| Thiourea | 100 ± 0.1 | 54.56 ± 4.17 |
|
| -a | –b |
|
| 11 ± 3.3 | – |
|
| N.s. | – |
|
| N.s. | – |
|
| - | – |
|
| 1 ± 0.2 | – |
|
| - | – |
|
| - | – |
|
| 3 ± 3.0 | – |
|
| N.s. | – |
|
| 7 ± 3.1 | – |
|
| 7 ± 3.0 | – |
|
| 4 ± 1 | – |
|
| 56 ± 4 | – |
|
| - | – |
|
| 100 ± 1.5 | 4.67 ± 0.53 |
|
| 100 ± 2.1 | 45.37 ± 0.78 |
|
| - | – |
|
| - | – |
|
| 47 ± 0.1 | – |
|
| - | – |
|
| N.s. | – |
N.s. Not soluble
aNo inhibition
bNot determined
Porcine pancreatic lipase inhibitory activity of synthesized compounds
| Compound no. | % Inhibition |
|---|---|
|
| – |
|
| – |
|
| – |
|
| 16 |
|
| 33 |
|
| 22 |
|
| 20 |
|
| – |
|
| – |
|
| 68 |
|
| 63 |
|
| 75 |
|
| 73 |
|
| 6 |
|
| – |
|
| 1 |
|
| – |
|
| – |
|
| – |
|
| 33 |
| Orlistat | 99 |
| DMSO control | – |
| Positive control | – |
All compounds were screened at concentration of 6.25 μg mL−1